Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Ceftobiprole in the Treatment of Patients With Acute Bacterial Skin and Skin Structure Infections

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03137173
Recruitment Status : Completed
First Posted : May 2, 2017
Results First Posted : May 18, 2020
Last Update Posted : October 26, 2020
Sponsor:
Information provided by (Responsible Party):
Basilea Pharmaceutica

Brief Summary:
This was a randomized, double-blind, active-controlled, parallel-group, multicenter study in adult hospitalized patients to establish the safety and efficacy of ceftobiprole medocaril compared with vancomycin plus aztreonam in the treatment of acute bacterial skin and skin structure infections (ABSSSIs).

Condition or disease Intervention/treatment Phase
Acute Bacterial Skin and Skin Structure Infections Drug: ceftobiprole medocaril Drug: vancomycin+aztreonam Phase 3

Detailed Description:

This was a randomized, double-blind, active-controlled, parallel-group, multicenter study in adult hospitalized patients with ABSSSIs. Randomization was stratified by study site and type of ABSSSI (with major cutaneous abscess comprising ≤ 30% of the Intent-to-Treat [ITT] population).

Primary endpoint for FDA: Early clinical response based on the percent reduction in lesion size at 48-72 hours compared to baseline in patients who did not receive rescue therapy and were alive, in the ITT population.

Primary endpoint for EMA: Investigator-assessed clinical success at the test-of-cure (TOC) visit 15-22 days after randomization, in the co-primary ITT and Clinically Evaluable (CE) populations.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 679 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized, Double-blind, Multicenter Study to Establish the Safety and Efficacy of Ceftobiprole Medocaril Compared With Vancomycin Plus Aztreonam in the Treatment of Acute Bacterial Skin and Skin Structure Infections
Actual Study Start Date : February 19, 2018
Actual Primary Completion Date : April 22, 2019
Actual Study Completion Date : April 22, 2019

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: ceftobiprole medocaril
Patients treated with ceftobiprole medocaril 500 mg q8h (with dose adjustment for renal impairment).
Drug: ceftobiprole medocaril
ceftobiprole 500 mg was to be administered every 8 hours as a 2-hour IV infusion (with dose adjustment for renal impairment). The treatment duration was for a minimum of 5 days and a maximum of 10 days. Treatment could be extended up to 14 days if in the investigator's opinion this was required, and the extension was approved by the sponsor's medical monitor.
Other Name: ceftobiprole

Active Comparator: vancomycin+aztreonam
Patients treated with vancomycin 1000 mg (or 15 mg/kg) q12h plus aztreonam 1000 mg q12h (both with dose adjustment for renal impairment).
Drug: vancomycin+aztreonam

Vancomycin 1000 mg (or 15 mg/kg) was to be administered every 12 hours (with dose adjustment for renal impairment) as 2-hour IV infusion. Vancomycin dose adjustment for morbidly obese and hypermetabolic patients was to be done according to local standard of care. When locally available, vancomycin trough testing (VTT) might have been used by the unblinded pharmacist or delegate to adjust the vancomycin dose. The treatment duration was for a minimum of 5 days and a maximum of 10 days. Treatment could be extended up to 14 days if in the investigator's opinion this was required, and the extension was approved by the sponsor's medical monitor.

Aztreonam 1000 mg was to be administered as a 0.5-hour IV infusion every 12 hours. If CLCR was < 30 mL/min (i.e., severe renal impairment), the aztreonam dosage regimen was to be adjusted. The requirement to continue aztreonam therapy beyond Day 3 was to be reassessed at the 72-hour study visit.





Primary Outcome Measures :
  1. Early Clinical Response [ Time Frame: 48-72 hours after start of study drug treatment ]
    Comparison of early clinical response, including ≥ 20% reduction from baseline in the primary lesion area (based on ruler measurements), survival for ≥ 72 hours and no rescue therapy in the ITT population


Secondary Outcome Measures :
  1. Investigator-assessed Clinical Success in the ITT Population [ Time Frame: 15-22 days after randomization ]
    Comparison of investigator-assessed clinical success (based on resolution of baseline signs and symptoms of the primary infection) in the ITT population

  2. Investigator-assessed Clinical Success in the Clinically Evaluable (CE) Population [ Time Frame: 15-22 days after randomization ]
    Comparison of investigator-assessed clinical success (based on resolution of baseline signs and symptoms of the primary infection) in the clinically evaluable (CE) population



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

INCLUSION CRITERIA

  1. Male or female, aged ≥18 years.
  2. Diagnosis of ABSSSI, meeting at least one of the definitions in (a) to (c) below. Local symptoms must have started within the 7 days prior to the Screening visit:

    1. Cellulitis/erysipelas, defined as a diffuse skin infection characterized by all of the following within 24 hours:

      • i. Rapidly spreading areas of erythema, edema, and/or induration with a minimum total lesion surface area of 75cm^2
      • ii. No collection of pus apparent upon visual examination
      • iii. At least two of the following local signs of infection:

        • erythema
        • induration
        • localized warmth
        • pain or tenderness on palpation
        • swelling/edema
    2. Major cutaneous abscess, defined as infection characterized by a collection of pus within the dermis or deeper that is apparent upon visual examination before or after therapeutic intervention and is accompanied by all of the following within 24 hours:

      • i. Erythema, edema and/or induration with a minimum total lesion surface area of 75 cm^2.
      • ii. At least two of the following local signs of infection:

        • fluctuance
        • incision and drainage required
        • purulent or seropurulent drainage
        • localized warmth
        • pain or tenderness on palpation
    3. Wound infection, defined as infection of any apparent break in the skin characterized by at least one of the following:

      • i. Superficial incision/surgical site infection meeting all of the following criteria:

        • involves only the skin or subcutaneous tissue around the incision (does not involve fascia).
        • occurs within 30 days of procedure.
        • purulent drainage (spontaneous or therapeutic) with surrounding erythema, edema and/ or induration with a minimum total lesion surface area of 75cm^2.
      • ii. Post-traumatic wound (including penetrating trauma, e.g., needle, nail, knife, insect and spider bites) meeting the following criterion within 24 hours:

        • Purulent drainage (spontaneous or therapeutic) with surrounding erythema, edema and/or induration with a minimum total lesion surface area of 75cm^2.
  3. At least one of the following regional or systemic signs of infection at the Screening visit:

    1. Lymph node tenderness and volume increase, or palpable lymph node proximal to the primary ABSSSI.
    2. Fever > 38 °C/100.4 °F measured orally, > 38.5 °C / 101.3 °F measured tympanically, > 37.5 °C / 99.5 °F measured by the axillary method, or > 39 °C / 102.2 °F measured rectally.
    3. White blood cell (WBC) count > 10.0 × 10^9/L or < 4.0 × 10^9/L.
    4. > 10% immature neutrophils (band forms).
  4. Requirement for IV antibacterial treatment.
  5. Willing and able to adhere to study procedures (including prohibitions and restrictions) as specified in this protocol.
  6. Willing and able to remain hospitalized (in a hospital or equivalent medical confinement or clinical research unit) until completion of the early-clinical-response assessment for the primary endpoint.
  7. Informed consent signed by the patient, or their legally acceptable representative if appropriate, indicating that they understand the purpose of, and procedures required for, the study, and are willing to participate.

EXCLUSION CRITERIA

Patients meeting any one of the following:

  1. Use of any systemic antibacterial treatment within 14 days, or topical antibacterial administration on the primary lesion within 96 hours, before first infusion of study drug.

    Exception: Receipt of a single dose of a short acting (half-life ≤ 12 hours) antibacterial therapy (e.g., for surgical prophylaxis) within > 3 days before randomization (i.e., patients cannot have received any antibacterial treatment within 72 hours of randomization).

  2. Contraindication to the administration of either of the study treatments, including known clinically-relevant hypersensitivity to related antibacterial treatments (e.g., beta-lactam and glycopeptide antibiotics), or to metronidazole if required as adjunctive therapy.
  3. Participation in any other clinical study within the 30 days prior to randomization, or any prior participation in this study.
  4. The primary ABSSSI is an uncomplicated skin and skin structure infection, such as furuncles, minor abscesses (area of suppuration not surrounded by cellulitis/erysipelas), impetiginous lesions, superficial or limited cellulitis/erysipelas, or minor wound infections (e.g., stitch abscesses).
  5. The primary ABSSSI is due to, or associated with, any of the following:

    1. Diabetic foot infection, gangrene, or perianal abscess.
    2. Concomitant infection at another site (e.g., septic arthritis, endocarditis, osteomyelitis), not including a secondary ABSSSI lesion.
    3. Infected burns.
    4. Decubitus or chronic skin ulcer, or ischemic ulcer due to peripheral vascular disease (arterial or venous).
    5. Any evolving necrotizing process (e.g., necrotizing fasciitis).
    6. Infections at vascular catheter sites, or involving thrombophlebitis.
  6. The primary ABSSSI is associated with, or in close proximity to, a prosthetic device.
  7. Patients who are placed in a hyperbaric chamber as adjunctive therapy for the ABSSSI.
  8. Patients expected to require more than two surgical interventions in the operating room for the ABSSSI.
  9. Severe sepsis or septic shock.
  10. Significant or life-threatening condition (e.g., endocarditis, meningitis) that would confound, or interfere with, the assessment of the ABSSSI.
  11. Another severe, acute or chronic medical condition, psychiatric condition, or laboratory abnormality that may increase the risks associated with study participation or administration of the investigational product, or may interfere with the interpretation of study results, and which, in the judgment of the investigator, would make the patient inappropriate for entry into this study.
  12. Receiving treatment for active tuberculosis.
  13. Absolute neutrophil count < 0.5 × 10^9/L.
  14. Recent history of opportunistic infections (i.e., within 30 days) if the underlying cause of these infections is still active (e.g., leukemia, transplant, acquired immunodeficiency syndrome [AIDS]).
  15. Patients receiving systemic steroids (> 40 mg per day prednisolone, or equivalent), or receiving immunosuppressant drugs.
  16. Requirement for peritoneal dialysis, plasmapheresis, hemodialysis, venovenous dialysis, or other forms of renal filtration, or expected to require such treatment before the TOC visit.
  17. Alanine transaminase (ALT) or aspartate transaminase (AST) levels ≥ 8× the upper limit of normal, OR severe hepatic disease with Child-Pugh class C.
  18. Women who are pregnant or nursing.
  19. Women who are of childbearing potential and unwilling to use an acceptable method of birth control during the study: female sterilization (bilateral tubal occlusion or oophorectomy, or hysterectomy) or male partner vasectomy; intrauterine device (IUD); combined (estrogen and progesterone containing) hormonal contraception (oral, vaginal ring, or transdermal patch) with an ethinylestradiol dose of at least 30 µg, plus use of male condoms (preferably with spermicides), female condoms, a female diaphragm or a cervical cap; or total sexual abstinence.

    Women are not considered to be of childbearing potential if they are either ≥ 1 year post-menopausal (where menopause is defined as at least 12 months of amenorrhea), or have a serum follicle stimulating hormone (FSH) measurement consistent with post-menopausal status according to local laboratory thresholds. An FSH measurement at Screening is to be obtained for post-menopausal females aged < 50 years, or for those aged ≥ 50 years who have been post-menopausal for < 2 years.

  20. Inability to start study-drug therapy within 24 hours of Screening.
  21. Patients with illicit drug use within 12 months of screening, including heroin, other opioids (unless prescribed for medical reasons unrelated to heroin substitution), cocaine / crack cocaine, and amphetamine or methamphetamine. Exception: Cannabis use.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03137173


Locations
Show Show 34 study locations
Sponsors and Collaborators
Basilea Pharmaceutica
Investigators
Layout table for investigator information
Study Director: Kamal Hamed, MD, MPH Basilea Pharmaceutica
  Study Documents (Full-Text)

Documents provided by Basilea Pharmaceutica:
Study Protocol  [PDF] July 11, 2018
Statistical Analysis Plan  [PDF] July 25, 2019

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Basilea Pharmaceutica
ClinicalTrials.gov Identifier: NCT03137173    
Other Study ID Numbers: BPR-CS-008
First Posted: May 2, 2017    Key Record Dates
Results First Posted: May 18, 2020
Last Update Posted: October 26, 2020
Last Verified: October 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Infection
Communicable Diseases
Skin Diseases, Bacterial
Bacterial Infections
Skin Diseases, Infectious
Skin Diseases
Vancomycin
Aztreonam
Ceftobiprole
Ceftobiprole medocaril
Cephalosporins
Anti-Bacterial Agents
Anti-Infective Agents